DDInter364 DDInter305
Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, deb
Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs have a decreased incidence of adverse effects compared to high dose monotherapy in the treatment of moderate hypertension. Carvedilol was granted FDA approval on 14 September 1995.
Chlorpropamide {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Carvedilol
Chlorpropamide {u} (Compound) causes {v} (Side Effect) Decreased appetite
Decreased appetite {u} (Side Effect) is caused by {v} (Compound) Carvedilol
Chlorpropamide {u} (Compound) resembles {v} (Compound) Glimepiride
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carvedilol
Chlorpropamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolbutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carvedilol
Chlorpropamide {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Propafenone
Propafenone {u} (Compound) resembles {v} (Compound) Carvedilol
Chlorpropamide {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is associated with {v} (Disease) hypertension
hypertension {u} (Disease) is treated by {v} (Compound) Carvedilol
Chlorpropamide {u} (Compound) causes {v} (Side Effect) Decreased appetite
Decreased appetite {u} (Side Effect) is caused by {v} (Compound) Propafenone
Propafenone {u} (Compound) resembles {v} (Compound) Carvedilol
Chlorpropamide {u} (Compound) causes {v} (Side Effect) Fluid retention
Fluid retention {u} (Side Effect) is caused by {v} (Compound) Anagrelide
Anagrelide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carvedilol
Chlorpropamide {u} (Compound) resembles {v} (Compound) Glimepiride
Glimepiride {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Carvedilol
Chlorpropamide {u} (Compound) resembles {v} (Compound) Sulfacetamide
Sulfacetamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolbutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carvedilol
Chlorpropamide (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Carvedilol (Compound)
Chlorpropamide (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Carvedilol (Compound)
Chlorpropamide (Compound) resembles Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol
Chlorpropamide (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol
Chlorpropamide (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Propafenone (Compound) and Propafenone (Compound) resembles Carvedilol (Compound)
Chlorpropamide (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is associated with hypertension (Disease) and hypertension (Disease) is treated by Carvedilol (Compound)
Chlorpropamide (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Propafenone (Compound) and Propafenone (Compound) resembles Carvedilol (Compound)
Chlorpropamide (Compound) causes Fluid retention (Side Effect) and Fluid retention (Side Effect) is caused by Anagrelide (Compound) and Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol
Chlorpropamide (Compound) resembles Glimepiride (Compound) and Glimepiride (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Carvedilol (Compound)
Chlorpropamide (Compound) resembles Sulfacetamide (Compound) and Sulfacetamide (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Carvedilol